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1. INTRODUCTION 
Pancreatitis, is a significant contributor to the “burden of gastrointestinal 
disease” in this country, according to a recent survey conducted by the 
American Gastroenterological Association (2001). In 1998 there were about 
1.2 million prevalent cases, with 327,000 inpatient and 530,000 physician 
office visits. The estimated total direct cost for this group of diseases was 
$2.1 billion in 1998.  
The cardinal manifestations of  chronic pancreatitis are glandular  (endocrine 
as well as exocrine insufficiency) and pain.  Modern medicine has brought the 
former under reasonable control by replacement therapy  (insulin, enzymes) but 
the latter continues to provide a major clinical challenge- “painful chronic 
pancreatitis is poorly understood and its management is controversial” 
(DiMagno 1999). Our lack of knowledge about what causes pain in 
pancreatitis has been a serious obstacle to improvement of the care of these 
patients, leading to various empirical approaches that are often based on 
purely anatomical grounds, are generally highly invasive and at best of 
marginal value (1998). Despite a wide variety of approaches covering 
innocuous (enzyme therapy),  minimally invasive  (endoscopic decompression, 
nerve blocks) and highly aggressive  (surgical decompression, pancreatectomy), 
no consensus has emerged and no form of treatment can be considered 
satisfactory at the present time. 
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2. CURRENT THEORIES ON THE PATHOGENESIS 
OF PAIN IN PANCREATITIS 
As with other organs, pain signaling from the pancreas involves at least 
three levels of neurons: the first is the primary nociceptor with its peripheral 
nerve endings located within the gland and its cell body located in the dorsal 
root ganglia. The central ends of these nociceptors terminate in the dorsal horn 
of the spinal cord where they make contact with neurons in the gray matter. 
Postsynaptic (i.e., second-order) neurons then travel cephalad within ascending 
pathways to synapse in several thalamic and reticular nuclei on their way to 
the sensory cortex. Signal transduction presents a unique challenge for 
nociceptors because unlike other sensory stimuli (such as light), noxious 
stimuli can take one of a variety of diverse forms including heat, pressure 
and chemical injury. In general, nociceptors convert noxious stimuli to an 
electrical response via specialized receptors such as the vanilloid receptor, 
TRPV1 and a variety of others. 
A minority of patients with chronic pancreatitis and pain have readily 
identifiable lesions such as pseudocysts that are relatively easy to treat 
surgically or endoscopically. In the others, pain has traditionally been thought  
to result from a variety of causes including elevated intrapancreatic pressures, 
ischemia and fibrosis. However, it is likely that these phenomena, while 
clearly associated with the disease, are not the root cause of the pain.  Instead, 
they probably are inciting factors on a background of neuronal sensitization 
induced by damage to the perineurium and subsequent exposure of the nerves  
to mediators and products of inflammation. The evidence for neuroimmune 
interactions in the pathogenesis of pain in humans with chronic pancreatitis 
has recently been reviewed (Di Sebastiano et al 2003). In general, the data is 
in keeping with evidence from the somatic literature that the persistent pain 
associated with peripheral tissue injury or inflammation results from long-
term changes in nociceptive processing that can involve both primary sensory 
neurons  (peripheral sensitization), as well as neurons in the spinal cord and 
higher structures  (central sensitization).  The gain of the entire system is 
therefore reset upwards, with the result that noxious stimuli now elicit a pain 
response that is much greater when compared with the normal state  (hyper- 
algesia). A further characteristic of the sensitized state is called allodynia, a 
term that refers to the phenomenon in which innocuous or physiological 
stimuli are perceived as painful. Conceptually, one can therefore postulate 
that patients with pancreatic neuronal sensitization may experience mechanical 
allodynia: pain in response to physiological changes in intraductal pressure 
(which would otherwise have not been perceived). Similarly, subsequent 
minor flare-ups of inflammation in such patients could also cause the associated 
pain to be felt as severe, rather than mild  (hyperalgesia).  
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3. A POTENTIAL ROLE FOR TRYPSIN IN 
PANCREATIC PAIN 
Nociceptive sensitization results from both early posttranslational 
changes as well as later transcription-dependent changes in effector genes, 
with both processes occurring in the peripheral terminals of the nociceptor 
and in dorsal horn neurons (Woolf and Costigan 1999). In turn these 
processes alter the sensitivity of the system with augmentation of the 
response to peripheral stimuli. Many of the elements of the “inflammatory 
2
cytokines (TNF, IL-1, IL-6), nitric oxide and caloric activity (heat)) are 
likely to result in early sensitization of pancreatic nociceptors in patients 
with pancreatitis as well. However, in addition to these ubiquitous elements, 
pancreatitis is also uniquely associated with a significant release and 
activation of endogenous proteases such as trypsin. Activated forms of these 
enzymes are detected in the pancreatic parenchyma and pancreatic juice of 
patients with pancreatitis (Steer 1993). Although activated enzymes are 
usually implicated in the pathogenesis of acute pancreatitis, they are 
probably also important in chronic pancreatitis, especially in the early stages.  
Perhaps the most conclusive evidence for the importance of the role of 
trypsin has come from the study of hereditary pancreatitis, which is a rare 
condition that leads to serial attacks of acute pancreatitis eventually followed 
by the development of chronic pancreatitis. Patients with hereditary 
pancreatitis have a mutation in the trypsinogen gene, which results in failure 
of cleavage and persistent tryptic activity, causing a pancreatitis that is very 
similar in its clinical picture to nonhereditary forms of chronic pancreatitis 
(Whitcomb et al 1996; Whitcomb 1999).  
Given the importance of trypsin and other proteases in the pathogenesis 
of pancreatitis, we hypothesized that they may also be key players in early 
forms of neuronal sensitization in this condition an effect mediated by 
specific receptors such as the protease activated receptors  (PARs),  a unique 
family of G-protein coupled receptors (Dery and Bunnett 1999). 
4. PROTEASE-ACTIVATED RECEPTORS  
Proteases abound in the body in both humoral  (thrombin, factor Xa) and 
cellular compartments  (trypsin, tryptase and other tryptic enzymes from 
mast cells), and are capable of a wide variety of biological functions, that 
extend beyond simple protein degradation. They can also act as biological 
signals, interacting with specific receptors in the form of either traditional 
soup” described in somatic pain models (including ions (K+, H+), amines 
(5-HT, histamine), kinins (bradykinin), prostanoids (PGE ), purines (ATP), 
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receptor-ligand coupling (such as those involving the coagulation factor Xa 
and urokinase) or through a recently described, novel method of receptor 
activation, requiring proteolytic cleavage. The latter is exemplified by the 
interactions of thrombin, trypsin, tryptase and perhaps other serine proteases, 
with what are called protease (or proteinase) -activated receptors  (PARs). 
This is a growing family of G-protein-coupled-receptors (Dery and Bunnett 
1999) that are biologically unique in that they are tethered to their own 
ligands under resting conditions. Upon exposure to certain serine proteases 
(e.g. thrombin for PAR1, PAR3 and PAR4 or trypsin for PAR1, PAR-2, 
PAR4), this ligand is “released” by proteolytic cleavage, subsequently binding 
and activating the receptor, which triggers a rise in intracellular calcium via 
phospholipase C activation and possibly, other mechanisms. Synthetic peptides 
(SLIGRL in the case of rat PAR-2) corresponding to the tethered ligand can 
also activate the receptor without the need for proteolysis. 
The original, and best studied protease activated receptor is the thrombin-
sensitive PAR-1 which is thought to play a role in inflammation and cell 
growth(Vergnolle et al 1999). Much less is known about  PAR-2 and its role 
in health and disease. However, it is expressed in a variety of gastrointestinal 
organs and tissues including enterocytes, pancreatic ductal epithelium, 
colonic and vascular smooth muscle and the enteric nervous system where it 
is speculated that it may be important in mediating the cytoprotective, vascular, 
secretory and motility responses to inflammation (Coelho et al 2003; Cottrell 
et al 2003; Amadesi and Bunnett 2004).  
5. THE PROTEASE ACTIVATED RECEPTOR-2 
AND NOCICEPTION 
Recently, others and we have begun exploring a role for protease-PAR-2 
signaling in primary afferent nociceptors. We first demonstrated the presence 
of PAR-2 mRNA and protein expression in adult rat thoracic DRG, as well as 
an increase in intracellular calcium in response to treatment of cultured DRG 
neurons with either trypsin or the PAR-2 agonist activating peptide (AcPeP) 
(Hoogerwerf et al 2001). Others have also shown that PAR-2 is expressed by 
a subset of peripheral nociceptive (peptidergic) neurons in the rat (Steinhoff 
et al 2000). Its activation results in the release of substance P and CGRP and 
the development of edema, suggesting a role for PAR-2 in the neurogenic 
component of inflammation.  Further, PAR-2 activation can mediate both 
thermal and mechanical hyperalgesia (Vergnolle et al 2001; Kawabata et al 
2001).  
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6. PAR-2 AND PANCREATIC NOCICEPTION 
Studies with the specific activating peptide, as described above, 
convincingly demonstrate that activation of PAR-2 may play a role in 
nociception. Sources of proteases capable of activating PAR-2 during 
inflammation include leukocytes and in particular, mast cells (rich in 
tryptase). However, in the context of pancreatitis, trypsin is an obvious 
endogenous candidate ligand for PAR-2  (see discussion above) and we have 
begun exploring the role of this system in pancreatic pain. 
The gene c-fos and its protein product fos are expressed in the spinal cord 
after various types of noxious stimuli, leading to its widely accepted use as a 
surrogate marker for nociceptive activation in response to peripheral 
stimulation (Harris 1998). We therefore determined whether the PAR-2 
agonist, AcPep (SLIGRL-NH2) could activate pancreatic nociceptors by 
studying the effect of intraductal pancreatic AcPep injections on Fos 
expression (Hoogerwerf et al 2001). AcPeP was able to directly activate 
pancreas-specific afferent neurons in vivo. As previously discussed noxious 
stimuli can either activate nociceptors or sensitize them, or both. The 
mechanisms and pathways involved may be separate. Sensitization is 
assessed by observing the effects of the proposed agent on the pain response 
to other forms of stimulation  (chemical, mechanical or thermal in nature).  
 We therefore tested the sensitizing effects, if any, of PAR-2 activation on 
the pancreatic nociceptive response to capsaicin, a potent and noxious agonist of 
the TRPV1 receptor. The TRPV1 (vanilloid) receptor is a key integrator of 
noxious thermal and chemical stimuli expressed by nociceptive neurons 
(Caterina and Julius 2001). We examined PAR-2 and TRPV1 expression in 
dorsal root ganglia receiving innervation from the pancreas  (thoracic segments, 
T8-T13). Ninety eight percent (259/263) of all TRPV1-IR neurons 
demonstrate PAR-2 IR. Conversely, 60%  (259/434) of PAR-2 IR neurons 
also show TRPV1-IR (Hoogerwerf et al 2004). After intraductal injection of 
AcPeo and enhanced spinal Fos response to capsaicin was observed, suggesting 
that PAR-2 activation may sensitize the nociceptors to stimulation by 
capsaicin. Examination of pancreatic histology did not reveal any evidence 
of pancreatitis, ruling out the possibility that the Fos response was secondary 
to induction of inflammation in response to intraductal infusion of AcPep.  
The natural agonist for PAR-2 includes trypsin and tryptase, with the 
former the obvious candidate in the setting of pancreatitis. We therefore tested 
the the effect of different doses of intraductal pancreatic trypsin injections on 
FOS expression was studied in vivo and showed that it significantly increased 
FOS expression over boiled trypsin in a dose-dependent manner in spinal 
segments receiving signals from the pancreas (Hoogerwerf et al 2004). We 
also examined whether infusion of trypsin into the pancreatic duct could 
provoke a behavioral pain response in awake rats.  To test this we used a 
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7. CONCLUSIONS  
The studies described above have led the development of a plausible 
model in which PAR-2 contributes to nociceptive signaling and sensitization 
and may provide a novel link between inflammation and pain in pancreatitis  
(Figure 1). Activated trypsin in the inflamed pancreas may stimulate PAR-2 
on peripheral sensory neurons, resulting in their excitation and central 
release of neurotransmitters such as substance P (SP) and CGRP in the spinal 
cord. This, in turn, can cause excitation of second-order neurons in the dorsal 
horn to activate ascending pathways that can relay nociceptive information 
to the brain. Thus, suppression of trypsin activity appears to be a legitimate 
target for the relief of pain in pancreatitis, independent of its effects on 
inflammation. If validated, these findings have major implications for the 
pathogenesis of pain in chronic pancreatitis and will provide novel targets 
for analgesic therapy.   
surrogate assay for visceral pain, the visceromotor reflex (VMR). Acute 
visceral pain can cause reflex contractions of somatotopically-innervated 
skeletal muscle, which can be measured by electromyography (EMG). Infusion 
of trypsin as well as AcPep into the pancreatic duct significantly increased 
EMG activity of the acromiotrapezius muscle suggesting that trypsin can 
induce a behavioral nocisponsive effect in conscious rats. To determine  
whether  direct  activation  of  PAR-2  produces  a  similar nocisponsive effect 
as trypsin, the PAR-2 agonist, AcPep (1 mM), was injected into the pancreas. 
We examined cross de-sensitization of the nocisponsive effect to provide 
evidence that trypsin and PAR-2 AcPep activate the same receptor. Infusion 
of the pancreatic duct with AcPep significantly decreased subsequent responses 
to trypsin. 
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Figure 1: Proposed involvement of PAR-2 in nociceptive signaling in pancreatitis. 1. In 
pancreatitis, PAR-2 receptors on sensory neurons are activated by proteases such as trypsin 
released from injured pancreatic epithelial cells. Degranulation of mast cells releases  
tryptase that also acts on PAR-2 receptors. 2. PAR-2 stimulated release of CGRP and SP 
occurs peripherally, which further amplifies inflammation and mast cell degranulation.  
3. Central release of these neurotransmitters leads to activation of nociceptivepathways and 
an increase in Fos expression. DRG = dorsal root ganglion. From Hoogerwerf et al 2001 with 
permission. 
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